EXEL News and Press, Exelixis Inc.

2026-03-04 01:52:14 ET Exelixis, Inc. (EXEL) TD Cowen 46th Annual Health Care Conference March 3, 2026 1:10 PM EST... Read the full article on Seeking Alpha For further details see: Exelixis, Inc. (EXEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

2026-02-28 04:57:00 ET Exelixis (NASDAQ: EXEL) is a relatively small biotech company with big dreams -- to become, as its executives said at a presentation in December, a "top five solid tumor oncology company." The company has a blockbuster drug that's funding its pipel...

- Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen 46 th Annual Health Care Conference: Exelixis is sche...

Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Feb. 24, 2026 /CNW/ -- USA News Group News Commentary , The global oncology market is on track to nearly triple in ...

2026-02-20 16:05:00 ET While not the most popular biotech company on the market, Exelixis (NASDAQ: EXEL) has been quietly making a name for itself over the past five years, while delivering strong financial results and solid returns. The good news is that the company could still...

2026-02-20 11:04:14 ET This article is part of a series that provides an ongoing analysis of the changes made to Renaissance Technologies US stock portfolio on a quarterly basis. It is based on their 13F Form filed on 02/12/2026. Please check out our last article for the changes...

2026-02-12 06:15:08 ET H.C. Wainwright analyst issues BUY recommendation for EXEL on February 12, 2026 11:05AM ET. The previous analyst recommendation was Buy. EXEL was trading at $42.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...

2026-02-10 20:55:10 ET More on Exelixis Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval Exelixis: High-Growth Oncology Name Trading At A Discount Exelixis Non-GAAP EPS of $0.97 beats by...

2026-02-10 20:54:20 ET Exelixis, Inc. (EXEL) Q4 2025 Earnings Call February 10, 2026 5:00 PM EST Company Participants Andrew Peters - Senior Vice President of Strategy Michael Morrissey - CEO, President & Director Christopher Senner - Executive VP & CFO ...

2026-02-10 18:33:35 ET Image source: The Motley Fool. Tuesday, February 10, 2026 at 5:00 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading